New chemotherapeutic agents: Update of major chemoradiation trials in solid tumors

Oncology

Volumn 63, Issue SUPPL. 2, 2002, Pages 29-38

  Curran, Walter J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Chemoradiation; Combined modality therapy; Locoregional control; Radiotherapy; Solid tumors

Indexed keywords

ANGIOSTATIN; ANTIINFECTIVE AGENT; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; FLUOROURACIL; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; R 11577; SEMAXANIB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

CANCER CONTROL; CANCER SURVIVAL; ESOPHAGUS CANCER; HUMAN; LARYNX CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; ONCOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION; RADIOSENSITIVITY; REVIEW; SOLID TUMOR; SYSTEMIC THERAPY; UTERINE CERVIX CANCER;

ALKYL AND ARYL TRANSFERASES; ANGIOGENESIS INHIBITORS; ANGIOSTATINS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOSE FRACTIONATION; DRUGS, INVESTIGATIONAL; ENDOTHELIAL GROWTH FACTORS; ENZYME INHIBITORS; ESOPHAGEAL NEOPLASMS; FARNESYLTRANSTRANSFERASE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INDOLES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOENZYMES; LARYNGEAL NEOPLASMS; LUNG NEOPLASMS; LYMPHOKINES; MALE; MEMBRANE PROTEINS; NEOPLASMS; PEPTIDE FRAGMENTS; PLASMINOGEN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTATIC NEOPLASMS; PYRROLES; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036911505     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067145     Document Type: Review

References (32)

1. Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR: Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8344 trial. J Natl Cancer Inst 1996;88:1210-1215.
2. Sause W, Kolesar P, Taylor S IV, Johnson D, Livingston R, Komaki R, Emami B, Curran WJ Jr, Byhardt R, Dar AR, Turrisi A III: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000;117:358-364.
3. Belani CP: Combined modality therapy for un-resectable stage III non-small cell lung cancer. New chemotherapy combinations. Chest 2000;117:127S-132S.
4. Gaspar LE: Optimizing chemoradiation therapy approaches to unresectable stage III non-small cell lung cancer. Curr Opin Oncol 2001;13:110-115.
5. Schiller JH: Novel therapies in lung cancer management. Oncology 2001;61(suppl 1):1-2.
6. Glaser CM, Millesi W, Kornek GV, Lang S, Schull B, Watzinger F, Selzer E, Lavey RS: Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preopera-tive chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001;50:705-715.
7. Harrison LB, Shasha D, Shiaova L, White C, Ramdeen B, Portenoy R: Prevalence of anemia in cancer patients undergoing radiation therapy [abstract]. Proc Am Soc Clin Oncol 2000;19:1851a.
8. Shasha D, Belani CP, George MJ, Harrison LB: Epoetin alfa once weekly increases hemoglobin and improves quality of life in anemic lung cancer patients receiving chemotherapy with or without concomitant or sequential radiation therapy [abstract]. J Clin Oncol 2001;20:1243.
9. George MJ, Vahdat LT, Shasha D, Harrison LB: Increased hemoglobin and improved quality of life with once weekly epoetin alfa in anemic breast cancer patients receiving concomitant or sequential chemoradiation [abstract]. J Clin Oncol 2001;20:2997.
10. Curran WJ Jr, Scott C, Langer C, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman TH, Rosenthal S, Byhardt R, Sause W, Cox J: Phase III comparison of sequential vs concurrent che-moradiation for patients with unresected stage III non-small cell lung cancer (NSCLC): Initial report of Radiation Therapy Oncology Group (RTOG) 9410 [abstract]. Proc Am Soc Clin Oncol 2000;19:1891a.
11. Turrisi AT, Kim K, Blum R, Sause WT, Liv-ingston RB, Komaki R, Wagner H, Aisner S, Johnson D: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. New Engl J Med 1999;340:265-271.
12. Forastiere AA, Berkey B, Maor M, Weber R, Goepfert H, Morrison WH, Glisson BS, Trotti A, Ridge JA, Chao C, Peters G, Lee D-J, Leaf A, Ensley J: Phase III trial to preserve the larynx: Induction chemotherapy and radiother-apy vs. concomitant chemoradiotherapy vs. ra-diotherapy alone, Intergroup Trial R91-11 [abstract]. J Clin Oncol 2001;20:4.
13. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compared hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.
14. Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, Coughlin CT, Pilepich MV: Updated results of the phase III Radiation Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49:937-946.
15. Pilephich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D: Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-1252.
16. Hanks GE, Lu J, Machtay M, Venkatesan V, Pinover W, Byhardt R, Rosenthal SA: RTOG Protocol 92-02: A phase III trial of the use of long-term androgen suppression following neoadjuvant hormonal cytoreduction and ra-diotherapy in locally advanced carcinoma of the prostate [abstract]. Proc Am Soc Clin Oncol 2000;19:1284a.
17. Grogan M, Thomas GM, Melamed I, Wong FLW, Pearcey RG, Joseph PK, Portelance L, Crook J, Jones KD: The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999;86:1528-1536.
18. Cooper JS, Guo MD, Herkovic A, Macdonald JS, Martenson JA, JR, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL: Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623-1627.
19. Morris M, Eifel P, Lu J, Levenback C, Grigsby P, Stevens R, Rotman M, Gershenson D, Mutch D: Pelvic radiation with concurrent chemotherapy vs. pelvic and para-aortic radiation for high-risk cervical cancer: A randomized RTOG clinical trial. New Engl J Med 1999;340:1137-1143.
20. Keys HM, Bundy BN, Stehman FB, Muder-spach LI, Chafe WE, Suggs CL, Walker JL, Gersell D: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. New Engl J Med 1999;340:1154-1161.
21. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S: Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. New Engl J Med 1999;340:1144-1153.
22. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC, Clarke-Pearson DL, Liao SY: Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17:1339-1348.
23. Fossella FV, Zinner RG, Komaki R, Lu R, Lee JS, Glisson BS, Pisters KM, Stevens CW, Kurie JM, Kies MS, Khuri FR, Kelly J, Liao Z, Hong WK: Gemcitabine with concurrent chest radiation followed by consolidation chemotherapy with gemcitabine plus cisplatin: A phase I trial for patients stage III non-small cell lung cancer [abstract]. J Clin Oncol 2001;20:1243.
24. Masferrer JL, Leahy KM, Koki AT, Zweiferl BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Can Res 2000;60:1306-1311.
25. Fong TAT, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Can Res 1999;59:99-106.
26. Dicker AP, Anne R, Bonanni R, Sidor C, Gu-bish E, Curran WJ Jr: Phase I trial results of recombinant human angiostatin protein and external beam radiation therapy. American Society of Clinical Oncology. 38th Annual Meeting, Orlando, Florida, 18-21 May 2002. Abstract 23.
27. Gibbs JB, Oliff A: The potential of farnesyl-transferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol 1997;37:143-166.
28. Gandara DR, Lovato LC, Albain KS, Leigh B, Lara PN, Crowley JJ, Stelzer K, Livingston RB: Prolonged survival in pathologic stage IIIB non-small cell lung cancer with concurrent chemoradiotherapy followed by consolidation docetaxel: A phase II study (S9504) of the Southwest Oncology Group (SWOG) [abstract]. Proc Am Soc Clin Oncol 2000;19:1916a.
29. Furuse K, Hosoe S, Masuda N, Suguira T, Yokota S, Ohbayashi K, Okazaki M, Nakamu-ra S, Tohda Y, Sawa S, Kamei T, Takada M: Impact of tumor control on survival in unresectable stage III non-small cell lung cancer treated with concurrent thoracic radiotherapy and chemotherapy [abstract]. Proc Am Soc Clin Oncol 2000;19:1893a.
30. Choi N, Baumann M, Flentjie M, Kellokumpu-Lehtinen P, Senan S, Zamboglou N, Kosmidis P: Predictive factors in radiotherapy for non-small cell lung cancer: Present status. Lung Cancer 2001;31:43-56.
31. MacManus MP, Hicks RJ, Ball DL, Kalff V, Matthews JP, Salimen E, Khaw P, Wirth A, Rischin D, McKenzie A: F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: Powerful correlation with survival and high impact on treatment. Cancer 2001;92:886-895.
32. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997;15:2996-3018.